Drug Toxicity

Dose-response relationships show how the frequency or severity of harmful effects changes as exposure increases. Researchers use these patterns to distinguish lower exposures with limited toxicity from levels associated with substantial harm. Comparing toxic-effect levels with effective doses helps estimate the therapeutic index, a measure that supports dose selection and the assessment of how closely therapeutic benefit approaches potential risk.

Toxicity may result from excessive activity at the drug’s intended target, unintended interactions with other molecular targets, or formation of reactive metabolites during drug processing. These mechanisms can initiate cellular injury and contribute to damage in organs such as the liver, kidneys, heart, or nervous system. Identifying the mechanism helps explain observed effects and informs safety evaluation.

Absorption, distribution, metabolism, and excretion determine how much drug or metabolite reaches tissues and how long it remains there. Differences among patients in these processes can therefore change exposure and susceptibility, even when administered doses are similar. Pharmacology uses these variations to interpret safety findings, refine dose selection, and recognize patients who may face greater risk.

Safety assessment progresses through toxicity studies that examine exposure, dose-response relationships, mechanisms of injury, and effects on susceptible organs. Findings from preclinical testing help identify potential hazards before clinical evaluation, while clinical safety testing examines adverse effects in people. Together, these stages provide evidence for selecting doses and balancing expected therapeutic benefit against possible harm.

Dose selection requires comparing the amount needed to produce a therapeutic effect with exposure levels associated with toxicity. The therapeutic index summarizes this relationship and helps indicate how much separation exists between benefit and harm. A narrower margin demands closer safety evaluation and monitoring, whereas the combined evidence supports decisions about acceptable dosing during development and clinical use.

Adverse-event monitoring collects information about unwanted effects observed during clinical use and safety testing. Pharmacologists can compare these findings with known dose-response patterns, suspected injury mechanisms, and patient differences to identify emerging risks. Monitoring is therefore part of risk management, helping teams reassess dosing, recognize organ-specific concerns, and maintain an appropriate balance between treatment benefit and harm.